Speaker Profile
PhD, CEO and Founder, Envoya
Biography
Dr. Orr has over 20 years experience in the fields of immunology and biotechnology. She focused her career on the design of polymer based immunotherapy. Shira holds a PhD in biotechnology engineering and completed her postdoc at Harvard Medical School.
Talk
The Revolution in Drug Delivery Using Bionanopolymer and AI
Revolutionizing the world of gene therapy through the development of polymerbased nanoparticles for targeted delivery. By harnessing the power of nanotechnology, Shira will discuss how her discovery overcomes the challenges associated with traditional gene therapies and unlock new possibilities for treating a wide range of genetic disorders and diseases.
Emerging Therapeutics Showcase:
Envoya
Envoya's mission is to revolutionize the treatment landscape for diseases such as cancer and rare disease by leveraging the power of biocompatible delivery nanoparticles that are tailored for unique payloads and specific target tissue.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
